CN113583033B - benzothiadiazole-TB-fluoroboron complex and synthesis method and application thereof - Google Patents
benzothiadiazole-TB-fluoroboron complex and synthesis method and application thereof Download PDFInfo
- Publication number
- CN113583033B CN113583033B CN202110869229.9A CN202110869229A CN113583033B CN 113583033 B CN113583033 B CN 113583033B CN 202110869229 A CN202110869229 A CN 202110869229A CN 113583033 B CN113583033 B CN 113583033B
- Authority
- CN
- China
- Prior art keywords
- compound
- benzothiadiazole
- complex
- formula
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001308 synthesis method Methods 0.000 title abstract description 5
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 13
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 7
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 60
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 238000002428 photodynamic therapy Methods 0.000 claims description 17
- 229940125898 compound 5 Drugs 0.000 claims description 14
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 10
- 229910015900 BF3 Inorganic materials 0.000 claims description 9
- 238000012984 biological imaging Methods 0.000 claims description 9
- 229910021645 metal ion Inorganic materials 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 5
- QBKFSWPZWWKKMJ-UHFFFAOYSA-N 4,7-dibromo-1,2,3-benzothiadiazole Chemical compound BrC1=CC=C(Br)C2=C1N=NS2 QBKFSWPZWWKKMJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 4
- 229920002866 paraformaldehyde Polymers 0.000 claims description 4
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000523 sample Substances 0.000 abstract description 5
- 239000007787 solid Substances 0.000 abstract description 5
- 238000003384 imaging method Methods 0.000 abstract description 4
- 238000004020 luminiscence type Methods 0.000 abstract description 4
- 238000006073 displacement reaction Methods 0.000 abstract description 3
- 238000004043 dyeing Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 229940126062 Compound A Drugs 0.000 description 32
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 29
- 238000002189 fluorescence spectrum Methods 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229910052796 boron Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 2
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- -1 [1,5] diazocine-2, 8-diyl Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 125000006617 triphenylamine group Chemical group 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- KYKBVPGDKGABHY-UHFFFAOYSA-N 4-bromo-2,1,3-benzothiadiazole Chemical compound BrC1=CC=CC2=NSN=C12 KYKBVPGDKGABHY-UHFFFAOYSA-N 0.000 description 1
- RUTNWXBHRAIQSP-UHFFFAOYSA-N 4-bromo-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1Br RUTNWXBHRAIQSP-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- LIQLLTGUOSHGKY-UHFFFAOYSA-N [B].[F] Chemical compound [B].[F] LIQLLTGUOSHGKY-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- OBISXEJSEGNNKL-UHFFFAOYSA-N dinitrogen-n-sulfide Chemical compound [N-]=[N+]=S OBISXEJSEGNNKL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000004770 highest occupied molecular orbital Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004768 lowest unoccupied molecular orbital Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1014—Carbocyclic compounds bridged by heteroatoms, e.g. N, P, Si or B
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
- C09K2211/1051—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms with sulfur
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a benzothiadiazole-TB-fluoroboron complex, a synthesis method and an application thereof, wherein the structural formula of the complex is shown as a formula A:the benzothiadiazole-TB-fluoroboron complex has large Stokes displacement, shows excellent luminescence performance, has excellent solid luminescence and has the potential of becoming an excellent OLED material; has wide pH application range and can be applied to human physiological environment; the probe has effective and good response to viscosity and can become a fluorescent probe with viscosity response; for Fe3+And Cu2+Has identification ability and is expected to be excellent Fe3+And Cu2+A fluorescent probe; the PDT photosensitizer has a good PDT effect, can be used for dyeing and imaging A549 cells, expands the types of the photosensitizer, and provides a new idea for synthesizing imaging-guided PDT photosensitizer.
Description
Technical Field
The invention belongs to the field of organic synthesis, analytical chemistry and biological imaging, and particularly relates to benzothiadiazole-containing material with excellent optical performanceThe synthesis of base-fluoroboron complexes and their use in metal ion recognition, photodynamic therapy and bioimaging.
Background
Photodynamic Therapy (PDT) is a new method for treating diseases such as tumors by using photosensitive drugs and laser activation. The traditional Chinese medicine composition has the advantages of low side effect, minimal invasion, no obvious drug resistance, high tumor destruction selectivity, easiness in combination with other therapies and the like, and becomes an important emerging means for accurate clinical tumor treatment. Photosensitizer is the core of PDT, and the traditional PDT photosensitizer has the problems of poor visible absorption, poor penetrability and the like, so more and more novel high-efficiency photosensitizer are developed. But based onThe photosensitizer of base (TB) skeleton is still in the primary stage, and only one relevant report is available.
Proper biocompatibility is an important factor affecting the performance of PDT photosensitizers and fluorescence imaging contrast agents, among others. The fluoroboric fluorescent dye has the advantages of high fluorescence quantum yield, higher molar extinction coefficient, narrower fluorescence absorption and emission peak, better light stability, good biocompatibility and the like, and is widely applied to the fields of biological medicine, pH probes, biological imaging, metal ion detection and the like. The coordination mode of the fluoroboric fluorescent compound mainly comprises the coordination of atoms such as N, N-, O-, N, O-and the like with a B atom (figure 1). The traditional fluorine boron fluorescent dye is a highly planar structure, has strong intermolecular pi-pi accumulation, causes large self-absorption and is easy to generate a fluorescence quenching phenomenon, has small Stokes displacement, is easy to be influenced by excitation light and scattered light, and has limited application in the fields of biological imaging and the like. Therefore, the fluoroboric compound is modified to obtain the fluorescent compound with large Stokes shift, which is favorable for expanding the application of the fluoroboric compound in the fields of biological and tissue imaging and other optics.
Disclosure of Invention
The invention aims to provide a benzothiadiazole-TB-fluoroboron complex, a synthesis method and application thereofThe base-fluoroboron complex is applied to the fields of metal ion identification, photodynamic therapy, biological imaging and the like.
A benzothiadiazole-TB-boron fluoride complex has a structural formula shown as formula A:
a method for synthesizing benzothiadiazole-TB-boron fluoride complex comprises the following steps:
(1) reacting the compound 1 with paraformaldehyde to obtain an intermediate 2, wherein the reaction formula is as follows:
(2) the intermediate 2 reacts with trimethyl borate to obtain an intermediate 3, and the reaction formula is as follows:
(3) the intermediate 3 and 4, 7-dibromo-benzothiadiazole 4 are subjected to coupling reaction to obtain a compound 5, wherein the reaction formula is as follows:
(4) hydrolysis of compound 5 affords compound 6, the reaction scheme is as follows:
(5) compound 6 reacts with boron trifluoride to give intermediate 7, of the formula:
(6) the intermediate 7 reacts with 4-triphenylamine borate 8 to obtain a compound 9, and the reaction formula is as follows:
the benzothiadiazole-TB-fluoroboron complex is applied as a photosensitizer for photodynamic therapy.
The benzothiadiazole-TB-fluoroboron complex is applied to biological imaging as a fluorescent material.
The benzothiadiazole-TB-fluoroboron complex is used as Fe3+And Cu2+The application of the fluorescent probe in metal ion recognition.
Has the advantages that: the benzothiadiazole-The base-fluoroboron complex has the following advantages:
(1) the synthesis method is simple, and the post-treatment is convenient;
(2) the material has large Stokes shift, excellent luminescence property, excellent solid-state luminescence and potential of becoming an excellent OLED material;
(3) has wide pH application range and can be applied to human physiological environment;
(4) the probe has effective and good response to viscosity and can become a fluorescent probe with viscosity response;
(5) for Fe3+And Cu2+Has identification ability and is expected to be excellent Fe3+And Cu2+FluorescenceA probe;
(6) the PDT photosensitizer has a good PDT effect, can be used for dyeing and imaging A549 cells, expands the types of the photosensitizer, and provides a new idea for synthesizing imaging-guided PDT photosensitizer.
Drawings
FIG. 1 is a schematic representation of the coordination of N, N-, O, O-and N, O-containing ligands to the B atom;
FIG. 2 is a UV absorption spectrum of Compound A in various solvents;
FIG. 3 shows fluorescence emission spectra of Compound A in different solvents;
FIG. 4 is the UV absorption spectra of compounds 5, 6, 7 and A in DMF;
FIG. 5 is the fluorescence emission spectra of compounds 5, 6, 7 and A in DMF;
FIG. 6 is a solid state fluorescence emission spectrum of compounds 5, 6 and A;
FIG. 7 is a fluorescence emission spectrum (a) and a line graph (b) of Compound A at different viscosities;
FIG. 8 is a fluorescence emission spectrum (a) and a line graph (b) of Compound A at different pH;
FIG. 9 is the fluorescence emission spectrum (a) of Compound A and the fluorescence emission spectrum (b) of the presence of different biological thiols;
FIG. 10 shows the concentration of Fe in compound A3+Fluorescence emission spectrum (a) and line graph (b) in the presence;
FIG. 11 shows the concentration of Fe in compound A3+Fluorescence emission spectrum (a) and standard curve (b) in the presence;
FIG. 12 is compound A-Fe3+The Job's curve of the system;
FIG. 13 is the toxicity of different concentrations of A on human bronchial epithelial-like cells (HBE);
FIG. 14 is the survival of A549 cells in the presence of A in the absence of light (L +) or in the presence of A;
FIG. 15 is a fluorescence micrograph of A vs A549 cells in the absence of illumination (L-) and illumination (L +);
FIG. 16 is intermediate of Compound 5 of the examples1H NMR spectrum;
FIG. 17 intermediate product materialization of the exampleProcess for preparation of Compound 513C NMR spectrum;
FIG. 18 is intermediate product of example Compound 61H NMR spectrum;
FIG. 19 is intermediate product of compound 6 of the example13C NMR spectrum;
FIG. 20 is of the product of example, Compound A1H NMR spectrum;
FIG. 21 is of the product of example, Compound A13C NMR spectrum.
Detailed Description
According to the invention, diazosulfide, boron fluoride and triphenylamine group are introduced into a TB skeleton, so that a diazosulfide-TB-boron complex is designed and synthesized, and the diazosulfide-TB-boron complex is applied to the fields of metal ion identification, photodynamic therapy, biological imaging and the like.
The structural formula of the benzothiadiazole-TB-boron complex is shown as A:
the present invention will be further described with reference to the following examples.
The following describes embodiments of the present invention in detail. The following examples are illustrative only and are not to be construed as limiting the invention. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention.
Examples
TABLE 1
In this embodiment, the method for synthesizing the benzothiadiazole-TB-fluoroboron complex includes the following steps:
reacting the compound 1 with paraformaldehyde to obtain an intermediate 2, reacting the intermediate 2 with trimethyl borate to obtain an intermediate 3, performing coupling reaction on the intermediate 3 and 4, 7-dibromo-benzothiadiazole 4 to obtain an intermediate 5, hydrolyzing the intermediate 5 to obtain an intermediate 6, reacting the intermediate 6 with boron trifluoride to obtain an intermediate 7, and reacting the intermediate 7 with 4-triphenylamine borate 8 to obtain a compound A. The method comprises the following specific steps:
(1) 4-bromo-3-methoxyaniline 1(50.0mmol) and paraformaldehyde (100.0mmol) were sequentially added to a 200mL round-bottomed flask, the flask was placed in a cryotank, the temperature was adjusted to-15 ℃, trifluoroacetic acid (100mL, about 30min after completion of dropwise addition) was slowly added to the flask with stirring, and the reaction was carried out at room temperature for 7 days. After completion of the reaction (TLC trace), the mixture was poured into ice water, adjusted to pH 9-10 with ammonia, cooled to room temperature, filtered with suction, and washed three times with ethanol to give intermediate 2.
(3) Adding the intermediate 2(5.0mmol) into a 100mL round-bottom flask, vacuumizing for three times, placing the flask in a low-temperature tank, adjusting the temperature to-78 ℃, adding 20.0mL anhydrous tetrahydrofuran into the flask under stirring, dropwise adding 2.5mL n-butyl lithium, reacting for 1h under argon protection, dropwise adding 0.6mL trimethyl borate, and then placing the flask at room temperature for reacting for 4 h. TLC trace to completion of reaction, dichloromethane extraction (30.0 mL. times.3) and spin-drying to give crude product. The crude product is purified by column chromatography (V)PE:VEA1: 5) to give intermediate 3 (70%).
(4) The intermediate 3(2.0mmol), 4, 7-dibromo-benzothiadiazole 4(4.8mmol), and tetrakis (triphenylphosphine) palladium (20% mmol,0.06g) were sequentially charged into a 100mL round-bottomed flask35.0mL of anhydrous toluene was added under an argon atmosphere, followed by addition of potassium carbonate (0.53g), and the reaction was carried out at 108 ℃ for 12 hours. After completion of the reaction (TLC chase), it was cooled to room temperature, extracted with dichloromethane (10.0 mL. times.3), the organic phase was dried over anhydrous sodium sulfate, and dried to give a crude product which was purified by column chromatography (V)DCM:VEA100:1) to give compound 5 (70%).
Compound 5: 7,7' - (3, 9-dimethoxy-6H, 12H-5, 11-dibenzo [ b, f ] [1,5] diazocine-2, 8-diyl) bis (4-bromobenzo [ c ] [1,2,5] thiadiazole)
1H NMR(400MHz,CDCl3)δ7.82(d,J=7.2Hz,1H,Ar-H),7.40(d,J=7.6Hz,1H,Ar-H),7.02(s,1H,Ar-H),6.85-6.61(m,5H,Ar-H),4.73-4.68(m,2H,-CH2-bridge),4.32-4.18(m,4H,TB-CH2*2),3.73(d,J=8.8Hz,6H,-OCH3*2).13C NMR(100MHz,CDCl3)δ159.1,156.3,153.9,153.4,149.7,149.0,132.0,131.2,130.2,129.7,127.8,122.2,120.0,119.8,112.8,111.3,109.6,107.9,66.8,58.2,58.1,55.8,55.4.
(5) And (3) putting the compound 5(2.0mmol) in a 50mL round-bottom flask, vacuumizing for three times, placing the flask in a low-temperature tank, adjusting to-15 ℃, adding 15.0mL of anhydrous dichloromethane, dropwise adding boron tribromide, moving the reaction bottle to room temperature after dropwise addition, and continuing to react for 12 hours under the protection of argon. After completion of the reaction (TLC chase), water was added for quenching, dichloromethane was extracted (10.0 mL. times.3), and the organic phase was dried over anhydrous sodium sulfate to give compound 6 (75%) after spin-drying.
Compound 6: 2, 8-bis (7-bromobenzo [ c ] [1,2,5] thiadiazol-4-yl) -6H,12H-5, 11-dibenzo [ b, f ] [1,5] diazocine-3, 9-diol
1H NMR(400MHz,DMSO-d6)δ8.06(d,J=7.6Hz,1H,Ar-H),7.58(d,J=7.6Hz,1H,Ar-H),7.22(s,1H,Ar-H),7.03(d,J=8.4Hz 1H,Ar-H),6.96(s,1H,Ar-H),6.79-6.71(m,3H,Ar-H),4.88-4.80(m,4H,TB-CH2*2),4.32(dd,J1=6.0Hz,J2=16.0Hz,2H,-CH2-bridge).13C NMR(100MHz,DMSO-d6)δ157.6,155.1,153.7,153.1,132.7,130.8,130.7,130.4,128.9,112.4,111.3,110.7,66.3,56.9.
(6) Compound 6 reacts with boron trifluoride to give intermediate 7, of the formula:
Weighing the compound 6(2.0mmol) in a 50mL round-bottom flask, placing the flask in a low-temperature tank, adjusting the temperature to-15 ℃, adding 15mL of anhydrous dichloromethane under the protection of argon, then adding 10mL of triethylamine (48mmol), stirring for 30min, then slowly dropwise adding 10mL of boron trifluoride diethyl etherate (48mmol), and after dropwise adding, continuing the reaction at room temperature for 24 h. After completion of the reaction (TLC chase), quenched with water, extracted with dichloromethane (10.0mL 3) and the crude product purified by column chromatography (V)DCM:VMeOH120:1) gave intermediate 7 (35%) which was used directly in the next reaction.
(7) The intermediate 7 reacts with 4-triphenylamine borate 8 to obtain a compound A, and the reaction formula is as follows:
Compound 7(2.0mmol), 4-triphenylamine borate 8(4.8mmol), tetrakis (triphenylphosphine) palladium (0.06g) and potassium carbonate (0.53g) were sequentially charged in a 100.0mL round-bottomed flask, and after purging three times, 35mL of anhydrous toluene was added, followed by reaction at 108 ℃ for 24 hours. After completion of the reaction (TLC follow-up), quenching with water, extraction with dichloromethane (20.0 mL. times.3) and column chromatography of the crude productPure (V)DCM:VMeOH80:1) to obtain compound a (54%).
A compound A:
1H NMR(400MHz,DMSO-d6)δ9.42(s,1H,Ar-H),9.24(s,1H,Ar-H),7.94(d,J=8.4Hz,2H,Ar-H),7.82(d,J=7.2Hz,1H,Ar-H),7.71(d,J=7.6Hz,1H,Ar-H),7.38–7.34(m,4H,Ar-H),7.12-7.06(m,8H,Ar-H),6.79(d,J=8.4Hz,1H,Ar-H),6.70(s,1H,Ar-H),6.49–6.42(m,2H,Ar-H),4.56(d,J=16.4Hz,2H,-CH2-bridge),4.20(s,2H,TB-CH2),4.06-4.01(m,2H,TB-CH2).13C NMR(100MHz,DMSO-d6)δ156.8,154.9,154.4,153.5,149.6,147.8,147.5,131.5,131.2,130.6,130.5,130.2,128.1,127.6,125.0,124.1,122.9,121.2,118.8,112.2,111.7,111.3,66.7,58.4,58.3.
solvation effect
The solvating effect of compound a obtained in the examples was tested, and the specific experimental protocol was as follows:
compound A is prepared into a concentration of 1 × 10 by using eight solvents of Dichloromethane (DCM), Tetrahydrofuran (THF), methanol (MeOH), acetonitrile (MeCN), dimethyl sulfoxide (DMSO), Toluene (Toluene), N, N-Dimethylformamide (DMF) and N-Hexane (N-Hexane) respectively-5The working solution in mol/L is tested for ultraviolet absorption spectrum and fluorescence emission spectrum, as shown in the attached figures 2 and 3.
As can be seen from FIGS. 2 and 3, Compound A is in a highly polar solventemA red shift occurs, indicating that it has ICT effects.
The ultraviolet absorption of A occurs around 300nm and is attributed to the B band absorption caused by pi-pi + transition on an aromatic ring; and its uv absorption at 410nm is attributed to the R-band absorption caused by n-pi + transition on the heteroatom.
Test for luminescent Properties
The solid-state fluorescence emission spectra of compound 5, compound 6 and compound a were tested (fig. 6).
The specific test scheme is as follows:
weighing 10-5Adding mol of compound 5, compound 6, compound 7 and compound A, and fixing the volume with DCM solution to the concentration of 1 × 10-5And (5) testing ultraviolet absorption, fluorescence emission and solid state fluorescence emission spectra of the sample at mol/L.
The spectral data for compound 5, compound 6, compound 7 and compound a are shown in table 2.
As is clear from table 2, the absorbance of compound a was greatly increased as compared with compound 6 and compound 7, and the absorbance of compound a was slightly increased as compared with compound 5, and under the same conditions, the molar absorption coefficient of compound a was 4 times that of compound 7, because the HOMO/LUMO energy gap of compound a was smaller, which was favorable for electron flow, and the molar absorption coefficient was increased. Compound A has a longer lambdaem(637nm) and greater Stokes shifts (328 nm). The large Stokes displacement and red light emission are beneficial to reducing the influence of excitation light and scattered light on fluorescence emission, can effectively shield biological background interference, and are beneficial to expanding the application of the fluorescent material in aspects of biological imaging and the like.
TABLE 2 spectroscopic Data (DCM) for Compounds 5, 6, 7 and A
aUltraviolet absorption wavelength in solution (slit is 2.5/5 nm);bmolar extinction coefficient ε is A/bC, unit is 1 × 105L mol-1·cm-1(ii) a c fluorescence emission wavelength in solution;dstokes shift in solution;erelative fluorescence quantum yield (reference: quinine sulfate);ffluorescence intensity in L.mol-1·cm-1;gSolid state excitation wavelength (slit 2.5/2.5 nm);ha solid state fluorescence emission wavelength;isolid-state Stokes shift. "-" indicates that the intensity was too low to test.
Viscosity response test
The response of compound A to viscosity (DMSO: glycerol is 1:9-10:0 in sequence) (lambda) was testedex310nm, slit: 5/10nm) (FIG. 7). As can be seen from FIG. 7, when the content of glycerin is increasedAt 10% and 20%, the fluorescence intensity slightly increased, probably because the increase in viscosity restricted intramolecular rotation of compound a, increasing its molecular rigidity, and thus slightly increased the fluorescence intensity. When the glycerol content was further increased, the fluorescence intensity began to decrease, probably because the increase of the hydrogen bond donor in the protic solvent caused the compound a to form intermolecular hydrogen bonds, resulting in fluorescence quenching.
pH response test
The response of Compound A to pH (. lamda.) was testedex310nm, slit: 5/10nm) (FIG. 8). As can be seen from FIG. 8, when the pH of the solution is 2-10, the fluorescence emission spectrum of the compound A has no obvious change, which indicates that the compound A has a wide pH application range and can be applied to human physiological environments.
Identification of metal ions and Biothiols
The response of Compound A to different ions and Biothiols (. lamda.) was testedex310nm, slit: 5/10nm, as shown in FIG. 9 and Table 3)
TABLE 3 Effect of Compound A with different Ionic, Biothiols
As can be seen from the combination of FIG. 9 and Table 3, the addition of Fe3+And Cu2+Then, the fluorescence intensity of compound a decreased by 99% and 78%, respectively; whereas when other metal ions, anions or biological thiols were added, the change in fluorescence intensity was negligible, indicating that Compound A is Fe3+The best recognition effect is achieved; the influence of the interfering ions on the compound A is small, which indicates that the compound A has little influence on Fe3+And Cu2+With more efficient recognition.
Compounds A and Fe3+After action, its lambdaemA significant red shift occurs, indicating that it is associated with Fe3+Coordination may occur. We therefore further investigated Compound A for Fe3+The recognition function of (2) (fig. 10). As shown in FIG. 10, the concentration was 1X 10-5-1×10-4In the range of M, with Fe3+Increase of concentration, changeThe fluorescence intensity of compound a decreased significantly until quenching.
The compound A-Fe was subsequently explored3+Standard curve of the system (FIG. 10, R)20.99) and limit of detection (LOD 1.2 × 10)-6mol·L-1)。
Identification of Fe for further exploration of Compound A3+For the reason of (2), a Job's curve is plotted (FIG. 11). As can be seen from FIG. 12, the compounds A and Fe3+No stable complex was formed. This is probably due to the O, N heteroatom in compound A being complexed with the B atom first, affecting Fe3+Coordination of (3). And the compound A can react with Fe3+The reason for the response may be that the V-shaped structure of the TB skeleton forms a semi-cavity, and Fe can be captured3+。
Cytotoxicity
Human bronchial epithelial-like (HBE) cells are used as a model, and the cytotoxicity of the compound A on the HBE cells is detected by adopting an MTT method. HBE cells were seeded in 96-well plates (1X 10)-5one/mL), 100. mu.L of medium was added to each well, CO at 37 ℃2After 24h incubation in the incubator, different concentrations of compound a were added to the seeded cells and incubated for 24 h. The plates were then washed 3 times with PBS buffer and 10. mu.L of MTT solution was added to each well for an additional 4h incubation. The medium in the wells was removed, 150 μ L of DMSO was added to each well to dissolve the blue-violet formazan (Formazam) crystals in the cells, and the cells were placed on a shaker and shaken at low speed for 5-7min to dissolve the crystalline material thoroughly. Finally, an enzyme-linked immunosorbent assay (ELISA) detector is used for measuring the absorbance values of each well at 560nm and 670 nm. Cytotoxicity was calculated by the following formula:
%viability=[∑(Ai/A0×100)/n]
in the formula AiRespectively the absorbance values of the compounds with different concentrations; a. the0Mean absorbance values for control wells without added compound; n (═ 3) represents three replicates.
Toxicity of c to HBE cells, normal cells, was tested using the MTT method (figure 12). As shown in fig. 13, compound a has low cytotoxicity to HBE and can be applied to an organism.
As shown in fig. 14, when not illuminated, a549 cells treated with compound a all showed extremely high survival rates, indicating that they had negligible dark toxicity; after the irradiation of light, the survival rate of the A549 cells is obviously reduced. Even if the concentration of 9 is reduced to 6.25. mu. mol. L-1The survival rate of a549 cells was still less than 40%, indicating that compound a has extremely low dark toxicity and high phototoxicity, and thus it has excellent PDT efficiency.
The half inhibition rate of the compound A on HBE and A549 cells is shown in Table 4, and the result shows that the compound A on the A549 cells has IC after illumination50Has a value less than HBE cells and has a very low IC50Values indicating excellent PDT efficiency and possibility of application to realistic treatment.
TABLE 4 half maximal Inhibitory Concentration (IC) of Compound A on both cells50)
Cell imaging assay
A549 cells are inoculated into a 96 micro-well plate and cultured for 24 h. The cells were subsequently treated with different concentrations (6.25, 12.50. mu. mol. L)-1) After further incubation for 24h, half of compound A was exposed to light for 2h and half was not exposed to light. The medium was changed to a medium containing calcein (CA, 100. mu.g/mL) for further 24h to stain live and dead cells. The plate was then washed 3 times with PBS buffer and incubated for 4h with MTT solution. The medium was removed and DMSO was added and shaken at low speed for 5-7 min. Finally, the cells were analyzed using fluorescence microscopy.
The in vitro photodynamic therapy effect was directly observed by live/dead cell staining (fig. 15).
As shown in fig. 15, none of the dark groups caused significant cell death, which is indicative of low dark toxicity of compound a; while the cells in the light group were almost all dead, indicating that compound a had better phototoxicity, which is consistent with the results in the experimental analysis of photodynamic therapy in vitro.
Compared with a synthetic raw material and an intermediate, the compound A can clearly image the A549 cells, is yellow in the cells, and can avoid the interference of the background color of the cells. As can be seen from the staining results, compound a can enter the cell and stain the cytoplasm, but not the nucleus.
The above description is only of the preferred embodiments of the present invention, and it should be noted that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the invention and these are intended to be within the scope of the invention.
Claims (5)
2. a method of synthesizing the benzothiadiazole-TB-fluoroboron complex of claim 1, characterized in that: the method comprises the following steps:
(1) reacting the compound 1 with paraformaldehyde to obtain an intermediate 2, wherein the reaction formula is as follows:
(2) the intermediate 2 reacts with trimethyl borate to obtain an intermediate 3, and the reaction formula is as follows:
(3) the intermediate 3 and 4, 7-dibromo-benzothiadiazole 4 are subjected to coupling reaction to obtain a compound 5, wherein the reaction formula is as follows:
(4) hydrolysis of compound 5 affords compound 6, the reaction scheme is as follows:
(5) compound 6 reacts with boron trifluoride to give intermediate 7, of the formula:
(6) the intermediate 7 reacts with 4-triphenylamine borate 8 to obtain a compound 9, and the reaction formula is as follows:
3. use of the benzothiadiazole-TB-fluoroboron complex according to claim 1 as a photosensitizer for photodynamic therapy.
4. Use of the benzothiadiazole-TB-fluoroboron complex according to claim 1 as a fluorescent material in biological imaging.
5. benzothiadiazole-TB-fluoroboron complex as described in claim 1 as Fe3+And Cu2+The application of the fluorescent probe in metal ion recognition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110869229.9A CN113583033B (en) | 2021-07-30 | 2021-07-30 | benzothiadiazole-TB-fluoroboron complex and synthesis method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110869229.9A CN113583033B (en) | 2021-07-30 | 2021-07-30 | benzothiadiazole-TB-fluoroboron complex and synthesis method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113583033A CN113583033A (en) | 2021-11-02 |
CN113583033B true CN113583033B (en) | 2022-05-10 |
Family
ID=78252281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110869229.9A Active CN113583033B (en) | 2021-07-30 | 2021-07-30 | benzothiadiazole-TB-fluoroboron complex and synthesis method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113583033B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530105A (en) * | 2014-12-29 | 2015-04-22 | 东莞理工学院 | Benzothiadiazole or benzodithiophene-bridged bis-boron-dipyrrolemethene (BODIPY) derivative organic dye and preparation method thereof |
CN108840865A (en) * | 2018-05-31 | 2018-11-20 | 吉林大学 | A kind of red organic fluorescence materials, the preparation method and applications of diazosulfide derivative |
CN110615802A (en) * | 2019-10-24 | 2019-12-27 | 江苏师范大学 | Benzimidazole quinazoline derivative and preparation method and application thereof |
CN111777575A (en) * | 2020-07-13 | 2020-10-16 | 江苏师范大学 | High-sensitivity fluorescent probe for detecting oxalyl chloride and preparation method and application thereof |
CN111848633A (en) * | 2020-08-17 | 2020-10-30 | 江苏师范大学 | coumarin-Tr star gers' base Fe3+ fluorescent probe and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10229370A1 (en) * | 2002-06-29 | 2004-01-15 | Covion Organic Semiconductors Gmbh | 2,1,3-benzothiadiazoles |
US8273885B2 (en) * | 2006-09-11 | 2012-09-25 | Eisai R&D Management Co., Ltd. | Fluoroboron compound having aromatic ring or salt thereof, and method for producing compound having cyclic ether-fused aromatic ring using the same |
-
2021
- 2021-07-30 CN CN202110869229.9A patent/CN113583033B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530105A (en) * | 2014-12-29 | 2015-04-22 | 东莞理工学院 | Benzothiadiazole or benzodithiophene-bridged bis-boron-dipyrrolemethene (BODIPY) derivative organic dye and preparation method thereof |
CN108840865A (en) * | 2018-05-31 | 2018-11-20 | 吉林大学 | A kind of red organic fluorescence materials, the preparation method and applications of diazosulfide derivative |
CN110615802A (en) * | 2019-10-24 | 2019-12-27 | 江苏师范大学 | Benzimidazole quinazoline derivative and preparation method and application thereof |
CN111777575A (en) * | 2020-07-13 | 2020-10-16 | 江苏师范大学 | High-sensitivity fluorescent probe for detecting oxalyl chloride and preparation method and application thereof |
CN111848633A (en) * | 2020-08-17 | 2020-10-30 | 江苏师范大学 | coumarin-Tr star gers' base Fe3+ fluorescent probe and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
A benzothiadiazole-based fluorescent sensor for selective detection of oxalyl chloride and phosgene;Wen-Qiang Zhang等;《Organic Chemistry Frontiers》;20170612;第4卷;第1719-1725页 * |
Synthesis and reactivity of dimethoxy-functionalised Troger’s base analogues;Qasim M.Malik等;《Tetrahedron》;20110612;第67卷;第5798-5805页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113583033A (en) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | A novel p-aminophenylthio-and cyano-substituted BODIPY as a fluorescence turn-on probe for distinguishing cysteine and homocysteine from glutathione | |
CN109970630B (en) | Two-photon fluorescent probe capable of targeting mitochondria and preparation method and application thereof | |
Shen et al. | Building Rhodamine-BODIPY fluorescent platform using Click reaction: Naked-eye visible and multi-channel chemodosimeter for detection of Fe3+ and Hg2+ | |
CN107603269A (en) | A kind of fluorescent dye based on naphthalimide, its preparation method and application | |
Zhu et al. | Novel BODIPY-based fluorescent probes with large Stokes shift for imaging hydrogen sulfide | |
CN105017288A (en) | Blue fluorescent compound and preparation method thereof | |
CN111303139A (en) | Compound with aggregation-induced emission performance and preparation method and application thereof | |
Zatsikha et al. | Functionalized bispyridoneannelated BODIPY–Bright long-wavelength fluorophores | |
CN110642882B (en) | Fluorescent probe with hydrogen peroxide detection and photodynamic cancer cell killing activity as well as preparation method and application thereof | |
Zhang et al. | Diketopyrrolopyrrole-based ratiometric fluorescent probe for the sensitive and selective detection of cysteine over homocysteine and glutathione in living cells | |
CN108864058A (en) | A kind of xanthone fluorochrome and application | |
Xiang et al. | Synthesis, spectral properties of rhodanine complex merocyanine dyes as well as their effect on K562 leukemia cells | |
Li et al. | AIE-based fluorescent boronate probe and its application in peroxynitrite imaging | |
CN109928940B (en) | Preparation of near-infrared fluorescent probe molecule for detecting hypochlorous acid based on basic blue-3 | |
CN114591632A (en) | Azaindole-hemicyanine dye, and synthesis method and application thereof | |
CN113416196B (en) | benzothiadiazole-TB compound and synthesis method and application thereof | |
CN111533761B (en) | Ratio type pH probe with organelle or protein targeting function and application thereof | |
CN113583033B (en) | benzothiadiazole-TB-fluoroboron complex and synthesis method and application thereof | |
Liu et al. | Highly efficient and selective red-emitting Ca2+ probe based on a BODIPY fluorophore | |
CN111548304A (en) | Derivative based on triphenylamine and preparation method and application thereof | |
Chevalier et al. | Rapid Synthesis of Unsymmetrical Sulforhodamines Through Nucleophilic Amination of a Monobrominated Sulfoxanthene Dye | |
CN112794813B (en) | Cyclobutene derivative for fluorescent labeling | |
CN109265476B (en) | Monofluoroboron fluorescent dye and preparation method and application thereof | |
CN113735864B (en) | D-benzothiadiazole-TB (-D) derivative and synthetic method and application thereof | |
CN112168976A (en) | Flavone derivative prodrug, synthesis and application as antitumor drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |